OBETICHOLIC ACID: AN OPTION FOR PATIENTS WITH PRIMARY BILIARY CHOLANGITIS

• At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
• Type: Poster
• By: GONZALEZ SUAREZ, Silvia (HOSPITAL VIRGEN DE LA SALUD, PHARMACY, Spain)
• Co-author(s): Silvia González Suárez: PHARMACY, HOSPITAL VIRGEN DE LA SALUD, TOLEDO, Spain
  Araceli Fernández-Corada Sánchez: PHARMACY, HOSPITAL VIRGEN DE LA SALUD, TOLEDO, Spain
  Ana Andrea García Sancristán: PHARMACY, HOSPITAL VIRGEN DE LA SALUD, TOLEDO, Spain
  Ana Domínguez Barahona: PHARMACY, HOSPITAL VIRGEN DE LA SALUD, TOLEDO, Spain
  Raúl López Álvarez: PHARMACY, HOSPITAL VIRGEN DE LA SALUD, TOLEDO, Spain
  Paloma Moya Gómez: PHARMACY, HOSPITAL VIRGEN DE LA SALUD, TOLEDO, Spain
  
• Abstract:

  Background

  Obeticholic acid is an orphan drug indicated in combination with ursodeoxycholic acid(UDCA), to treat primary biliary cholangitis(PBC) in adults non-responders to UDCA or when UDCA is not well tolerated.

  Methods

  Retrospective study of patients treated between July2017 and March2019. Patients information were reviewed from electronic
  ..

The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login